J&J Researchers Move Closer to Developing Universal Flu Vaccine
This article is for subscribers only.
Researchers at Johnson & Johnson are getting closer to developing a universal flu vaccine that could work against a number of strains of the virus, a holy grail for the medical field that could eliminate the need to formulate a new vaccine every year.
A study conducted by the Scripps Research Institute and J&J’s Janssen Pharmaceutical unit showed that, in mice and monkeys, a molecule designed in the lab to mimic a key part of the flu virus’s attack could protect against multiple influenza strains, not just one.